MKI67 and neoplasm: The IHC assays, in combination with anatomical stages (tumor size, regional nodal and distant organ metastasis), pathological features such as histological type and nuclear grade and an IHC-based proliferative marker, Ki67 (coded by the gene MKI67) not only determine which systemic therapy should be prescribed (predictive markers), but also serve as prognostic biomarkers forecasting long-term treatment outcomes [2,3].